| Date:2021/4/12   |
|--|
| Your Name: Ting Qian   |
| Manuscript Title: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript number (if known):  |
|  |
|  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone   |   |
| 2 | Grants or contracts from any entity (if not indicated   | Time frame: pastXNone   | 36 months   |
| 3 | in item #1 above).  Royalties or licenses   | XNone   |   |
| 4 | Consulting fees   | XNone   |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Your Name: Hui Zhang  Manuscript Title: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion | Date:        | _2021/4/12  |
|--|--------------|---|
| Manuscript Title: Knockdown of IncRNA THC338 inhibits esophageal cancer cells migration and invasion                       | Your Name:_  | Hui Zhang   |
| Manascript Title: knockdown of mekter roesso inhibits esophagear cancer cens inigration and invasion                       | Manuscript 1 | Title: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript number (if known):  | Manuscript r | number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | <b>X</b> None  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Date:2                | 021/4/12  |
|-----------------------|---|
| Your Name:            | Shaorong Yu   |
| <b>Manuscript Tit</b> | tle: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript nu         | umber (if known):   |
|                       |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone                                     |
|-----|--|---|
| 6   | Payment for expert testimony   | XNone                                     |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above o   | onflict of interest in the following box: |
|     |  |   |

| Date:      | _2021/4/12  |
|------------|---|
| Your Name: | Zhenzhang Chen  |
| Manuscript | Title: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript | number (if known):  |
|            |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Date:2        | 021/4/12   |
|---------------|--|
| Your Name:    | _ Hui Jia  |
| Manuscript Ti | itle: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript n  | umber (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone                                     |  |
|-----|--|---|--|
| 6   | Payment for expert testimony   | XNone                                     |  |
| 7   | Support for attending meetings and/or travel   | XNone                                     |  |
| 8   | Patents planned, issued or pending   | XNone                                     |  |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | _ XNone                                   |  |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | XNone                                     |  |
| 11  | Stock or stock options   | _ XNone                                   |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | _ XNone                                   |  |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |  |
| Ple | ease summarize the above c   | onflict of interest in the following box: |  |
|     |  |   |  |

| Date:                   | 2021/4/12   |
|-------------------------|---|
| Your Name:              | Fanyu Peng  |
| Manuscript <sup>1</sup> | Title: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript              | number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | <b>X</b> None  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Date: 2021/4/12               |   |
|-------------------------------|---|
| Your Name: Guochun Cao        |   |
|                               | 38 inhibits esophageal cancer cells migration and invasion  |
| Manuscript number (if known): |   |
|                               |   |
| • • • •                       | close all relationships/activities/interests listed below that are ed" means any relation with for-profit or not-for-profit third |

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Date:        | 2021/4/12   |
|--------------|---|
| Your Name:_  | _ Jianwei Lu  |
| Manuscript 7 | Fitle: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |
| Manuscript r | number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Date:2                        | 021/4/12  |  |
|-------------------------------|---|--|
| Your Name:                    | Delin Liu   |  |
| Manuscript Ti                 | tle: Knockdown of IncRNA TUC338 inhibits esophageal cancer cells migration and invasion |  |
| Manuscript number (if known): |   |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert | X None  X None                            |
|-----|--|---|
|     | testimony  |   |
| 7   | Support for attending meetings and/or travel   | XNone                                     |
| 8   | Patents planned, issued or pending   | XNone                                     |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone                                     |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                | XNone                                     |
| 11  | Stock or stock options   | XNone                                     |
| 12  | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone                                     |
| 13  | Other financial or non-<br>financial interests   | XNone                                     |
| Ple | ease summarize the above c   | onflict of interest in the following box: |
|     |  |   |

| Date:        | _2021/5/26  |
|--------------|---|
| Your Name:_  | Dawei Sun   |
| Manuscript 1 | Title: Knockdown of the expression of IncRNA TUC338 can inhibit the migration and invasion of |
| esophageal d | cancer cells  |
| Manuscript r | number (if known):  |
|              |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |

| 5   | Payment or honoraria for                       | <b>X</b> None              |                |
|-----|--|----------------------------|----------------|
|     | lectures, presentations,                       |                            |                |
|     | speakers bureaus,                              |                            |                |
|     | manuscript writing or educational events       |                            |                |
| 6   | Payment for expert                             | <b>X</b> None              |                |
|     | testimony                                      | XNone                      |                |
|     | ,  |                            |                |
| 7   | Support for attending                          | <b>X</b> None              |                |
|     | meetings and/or travel                         |                            |                |
|     |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |
| 8   | Patents planned, issued or                     | <b>X</b> None              |                |
|     | pending  |                            |                |
| 9   | Participation on a Data                        | X None                     |                |
| 9   | Safety Monitoring Board or                     | <b>X</b> None              |                |
|     | Advisory Board                                 |                            |                |
| 10  | Leadership or fiduciary role                   | <b>X</b> None              |                |
|     | in other board, society,                       |                            |                |
|     | committee or advocacy                          |                            |                |
| 11  | group, paid or unpaid                          |                            |                |
| 11  | Stock or stock options                         | <b>X</b> None              |                |
|     |  |                            |                |
| 12  | Receipt of equipment,                          | <b>X</b> None              |                |
|     | materials, drugs, medical                      |                            |                |
|     | writing, gifts or other                        |                            |                |
|     | services                                       |                            |                |
| 13  | Other financial or non-<br>financial interests | <b>X</b> None              |                |
|     | imanciai interests                             |                            |                |
|     |  |                            |                |
|     |  |                            |                |
| Ple | ease summarize the above c                     | onflict of interest in the | following box: |
| _   |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |
|     |  |                            |                |

| X I certify that I have answered every question and have not altered the wording of any of the questions on the form. | his |
|---|-----|
|   |     |
|   |     |
|   |     |
|   |     |
|   |     |
|   |     |
|   |     |
|   |     |
|   |     |
|   |     |